Recursion Pharmaceuticals, INC DEF 14A proxy statements

Recursion Pharmaceuticals has filed a definitive proxy statement with the SEC.

Recursion Pharmaceuticals' 2025 proxy statement outlines its strategy to leverage AI and data to transform drug discovery, including a major merger with Exscientia and advancements in clinical programs.

Recursion Pharmaceuticals and Exscientia amend their transaction agreement to include the appointment of Exscientia board members to Recursion's board following the acquisition.

Recursion Pharmaceuticals will release its Q3 2024 financial results on November 6th and plans an investor update call on November 20th, following the anticipated close of its merger with Exscientia.

Recursion Pharmaceuticals is set to acquire Exscientia in an all-stock transaction aimed at combining their AI-driven drug discovery platforms.

Recursion Pharmaceuticals emphasizes the strategic rationale behind its proposed acquisition of Exscientia, focusing on the convergence of biology and chemistry expertise to enhance drug discovery.

Recursion Pharmaceuticals and Exscientia leaders discussed the strategic rationale, synergies, and integration plans for their proposed merger at the Morgan Stanley Healthcare Conference on September 4, 2024.

Recursion Pharmaceuticals is set to acquire Exscientia in a stock-for-stock transaction valued at approximately $775 million, aiming to create a leading technology-enabled drug discovery platform.

Recursion Pharmaceuticals gains further commitment for its acquisition of Exscientia as Evotec SE, holding approximately 11% of Exscientia's shares, agrees to vote in favor of the transaction.

Recursion Pharmaceuticals is set to acquire Exscientia in an all-stock deal valued at $688 million, aiming to create an end-to-end, tech-enabled drug discovery platform.

Recursion Pharmaceuticals will acquire Exscientia for $688 million in an all-stock transaction, combining their AI-driven drug discovery platforms to accelerate and reduce the cost of developing new medicines.

Recursion Pharmaceuticals will acquire Exscientia in a stock-based transaction, aiming to combine their AI-driven drug discovery platforms and pipelines.

Recursion Pharmaceuticals updates its proxy statement, announcing a change in its independent auditor from Ernst & Young LLP to PricewaterhouseCoopers LLP, the withdrawal of R. Martin Chavez as a nominee for Class III Director, and the election of Robert Hershberg as the new Chair of the Board.

Recursion Pharmaceuticals has filed a definitive proxy statement with the SEC.

Recursion Pharmaceuticals' proxy statement outlines the company's strategic achievements in 2023, including advancements in clinical programs, partnerships, and AI-driven drug discovery platform, while also detailing executive compensation and corporate governance matters.